• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重组组织型纤溶酶原激活剂(r-t-PA)与重组单链尿激酶型纤溶酶原激活剂(r-scu-PA)对兔肺血栓形成的协同纤溶作用

Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis.

作者信息

Schneider J, Friderichs E, Günzler W A, Flohé L

机构信息

Grünenthal GmbH, Center of Research, Aachen, FRG.

出版信息

Thromb Res. 1989 Oct 1;56(1):59-65. doi: 10.1016/0049-3848(89)90008-x.

DOI:10.1016/0049-3848(89)90008-x
PMID:2512686
Abstract

The mode of interaction between recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase-type plasminogen activator (r-scu-PA) has been investigated in in vivo experiments. 125J-fibrin-labeled clots were embolized via a jugular vein into the lungs of anesthetized rabbits. In saline-treated control rabbits the spontaneous lysis, shown as decrease in radioactivity of the retrieved clots, amounted to 10.4 +/- 1.4% at 255 min after the pulmonary embolization. r-t-PA (0.464 - 4.64 micrograms/kg.min) and r-scu-PA (4.64 - 46.4 microns/kg.min), infused for 60 min, produced dose-dependent lytic effects to a similar extent (maximum lysis rate 53.9 +/- 5.8 and 55.4 +/- 7.2%, resp.). When various ratios of submaximal doses of r-t-PA and r-scu-PA were combined the lytic effects of these combinations were not higher than the calculated summation of the lysis rates by the single components. The fractional dose-response curves of r-t-PA and r-scu-PA and the combination of them, fitted by linear regression analysis, are overlaying each other. The results indicate that r-t-PA and r-scu-PA produce in vivo lysis in rabbits with pulmonary embolized clots in a purely additive manner.

摘要

在体内实验中研究了重组组织型纤溶酶原激活剂(r-t-PA)与重组单链尿激酶型纤溶酶原激活剂(r-scu-PA)之间的相互作用模式。将125I标记的纤维蛋白凝块通过颈静脉栓塞到麻醉兔的肺中。在生理盐水处理的对照兔中,肺栓塞后255分钟时,取出的凝块放射性降低所显示的自发溶解率为10.4±1.4%。持续输注60分钟的r-t-PA(0.464 - 4.64微克/千克·分钟)和r-scu-PA(4.64 - 46.4微克/千克·分钟)产生了相似程度的剂量依赖性溶解作用(最大溶解率分别为53.9±5.8%和55.4±7.2%)。当将不同比例的次最大剂量的r-t-PA和r-scu-PA组合时,这些组合的溶解作用不高于单一组分溶解率的计算总和。通过线性回归分析拟合的r-t-PA、r-scu-PA及其组合的分数剂量反应曲线相互重叠。结果表明,r-t-PA和r-scu-PA在兔肺栓塞凝块的体内溶解过程中以纯粹相加的方式起作用。

相似文献

1
Additive fibrinolysis by recombinant tissue-type plasminogen activator (r-t-PA) and recombinant single-chain urokinase type plasminogen activator (r-scu-PA) in rabbit pulmonary thrombosis.重组组织型纤溶酶原激活剂(r-t-PA)与重组单链尿激酶型纤溶酶原激活剂(r-scu-PA)对兔肺血栓形成的协同纤溶作用
Thromb Res. 1989 Oct 1;56(1):59-65. doi: 10.1016/0049-3848(89)90008-x.
2
Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.组织型纤溶酶原激活剂(t-PA)、单链尿激酶型纤溶酶原激活剂(scu-PA)和尿激酶序贯输注对兔颈静脉血栓形成模型溶栓的协同作用。
Thromb Haemost. 1987 Oct 28;58(3):943-6.
3
Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.在仓鼠肺栓塞模型中推注注射与持续输注嵌合型(组织型纤溶酶原激活剂/尿激酶型纤溶酶原激活剂)纤溶酶原激活剂的溶栓特性比较。
Blood. 1991 Jul 1;78(1):125-31.
4
Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.嵌合组织型和尿激酶型纤溶酶原激活剂的溶栓及药代动力学特性
Circulation. 1991 Sep;84(3):1216-34. doi: 10.1161/01.cir.84.3.1216.
5
Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.组织型纤溶酶原激活剂(t-PA)、单链尿激酶型纤溶酶原激活剂(scu-PA)和尿激酶在体外血浆环境中对血凝块溶解不存在协同作用。
Thromb Haemost. 1986 Aug 20;56(1):35-9.
6
Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.一种由纤维蛋白片段D - 二聚体特异性人源化单克隆抗体和截短的单链尿激酶组成的重组嵌合纤溶酶原激活剂的溶栓和药代动力学特性
Thromb Haemost. 1992 Aug 3;68(2):170-9.
7
Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.单链尿激酶型纤溶酶原激活剂和组织型纤溶酶原激活剂在犬动脉血栓形成模型中的推注剂量反应特征。
Thromb Res. 1988 Nov 15;52(4):295-312. doi: 10.1016/0049-3848(88)90071-0.
8
Taprostene, a stable prostacyclin analogue, enhances the thrombolytic efficacy of saruplase (recombinant single-chain urokinase-type plasminogen activator) in rabbits with pulmonary embolized thrombi.
Prostaglandins. 1991 Jun;41(6):595-606. doi: 10.1016/0090-6980(91)90064-m.
9
Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).大剂量组织型纤溶酶原激活剂及血浆半衰期延长的杂交纤溶酶原激活剂(K2tu-PA:CGP 42935)的溶栓和出血作用
Thromb Haemost. 1993 Aug 2;70(2):294-300.
10
Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.重组葡萄球菌激酶与单链尿激酶型纤溶酶原激活剂组合的体外溶栓作用协同性。
Biochemistry (Mosc). 2003 Nov;68(11):1252-60. doi: 10.1023/b:biry.0000009141.17272.6c.